603392.SH
万泰生物
SSE · Healthcare · Biotechnology · CN
CNY 28.09
−8.17%Year over year
Reported trailing growth
- Revenue
- +2.5%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- -33.1%
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +16.6%
- EBITDA
- +4478.1%
- EPS
- +1426.0%
Three-year CAGR
- Revenue
- -45.4%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -34.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026